(90 days)
No
The description focuses on the material properties, design, and mechanical performance of a resorbable mesh for hernia repair. There is no mention of any computational or data-driven components that would suggest the use of AI or ML.
No
The device is a mesh used for anatomical reinforcement, which is not considered a therapeutic function. Its purpose is to physically support and strengthen weakened tissue, not to treat a disease or condition.
No
This device is a resorbable mesh intended for the reinforcement of abdominal wall soft tissues during ventral hernia repair, which is a therapeutic rather than a diagnostic function.
No
The device description clearly states it is a physical mesh made of resorbable material with physical grips, intended for surgical implantation. It is a hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "reinforcement of abdominal wall soft tissues where weakness exists in open procedures involving ventral hernia repair." This describes a surgical implant used directly on a patient's body during a procedure.
- Device Description: The description details a "fully resorbable bi-dimensional Poly-L-lactide, poly-trimethylene carbonate copolymer (PLLA/TMC) monofilament textile with monofilament PLLA/TMC absorbable grips." This is a physical mesh designed to be implanted.
- IVD Definition: In Vitro Diagnostics (IVDs) are medical devices used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to provide information about a person's health.
This device is clearly an implantable surgical mesh, not a device used for testing biological samples outside the body.
N/A
Intended Use / Indications for Use
Transorb™ Self-Gripping Resorbable Mesh is intended to be used for the reinforcement of abdominal wall soft tissues where weakness exists in open procedures involving ventral hernia repair.
Product codes
OWT, OOD, FTL
Device Description
Transorb™ Self-Gripping Resorbable Mesh is designed for ventral hernia repair when placed in an extraperitoneal space by open surgical approach. Transorb™ Self-Gripping Resorbable Mesh is made of a fully resorbable bi-dimensional Poly-L-lactide, poly-trimethylene carbonate copolymer (PLLA/TMC) monofilament textile with monofilament PLLA/TMC absorbable grips on one side. Transorb™ Self-Gripping Resorbable Mesh is available in different shapes and sizes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
abdominal wall
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Bench tests, in vitro and in vivo studies, biocompatibility testing, animal testing, human factors testing, shelf-life studies.
- Biocompatibility Testing: Performed according to ISO 10993. Tests included Cytotoxicity, Sensitization, Intracutaneous irritation, Acute systemic toxicity, Material mediated pyrogenicity, Hemolysis, Genotoxicity (bacterial reverse mutation -Ames, mouse lymphoma), Subacute systemic toxicity, Subchronic systemic toxicity, Local tissue effects (28D - 10W - 26W - 52W - 78W), In vivo degradation. All studies passed.
- Bench Testing: Evaluated physical and mechanical performances including Pore size, Surface density, Thickness, Bursting strength and deflection, Breaking strength and elongation at break, Tear strength, Suture pull-out strength. Results indicated substantial equivalence to the predicate.
- Animal Testing:
- Porcine study - Reinforcement performance: Evaluated reinforcement performance over 20 weeks, including mechanical performance (breaking strength – ball burst) of repaired abdominal wall defects and quality of tissue repair/mesh integration by histologic examination.
- Rabbit study – Degradation/Integration: Evaluated local tissue effects (ISO 10993-6), tissue integration, tissue ingrowth, and degradation profile.
- Porcine study – Gripping performance: Evaluated contribution of grips to mesh fixation in early stages post-implantation and quality of tissue repair/mesh integration by histologic examination.
- Human Factors Testing: Usability tests conducted in accordance with IEC 62366-1 demonstrated substantial equivalence for intended users, uses and use environments.
- Shelf-life: Real time studies demonstrated a shelf life of 36 months.
- Clinical data: This premarket submission did not rely on the assessment of clinical performance data to demonstrate substantial equivalence.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.3300 Surgical mesh.
(a)
Identification. Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo for the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
February 13, 2024
Sofradim Production Mickaël Nicolas Principal Regulatory Affairs Specialist 116, Avenue du Formans Trévoux, 01600, France
Re: K233661
Trade/Device Name: Transorb™ Self-Gripping Resorbable Mesh Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical Mesh Regulatory Class: Class II Product Code: OWT, OOD, FTL Dated: November 14, 2023 Received: November 15, 2023
Dear Mickael Nicolas:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
Your device is also subject to, among other requirements, the Quality System (OS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Digitally signed by Tek Tek N. N. Lamichhane -S Lamichhane -S Date: 2024.02.13 07:48:57 -05'00' Tek N. Lamichhane, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K233661
Device Name Transorb™ Self-Gripping Resorbable Mesh
Indications for Use (Describe)
Transort™ Self-Gripping Resorbable Mesh is intended to be used for the reinforcement of abdominal wall soft tissues where weakness exists in open procedures involving ventral hernia repair.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
| 510(k) Number | K233661 |
|---|---|
| Date Prepared: | January 11, 2024 |
| Submitter: | Sofradim Production (subsidiary of Covidien IIc) |
| 116, avenue du Formans | |
| 01600 Trevoux, France | |
| Telephone: +33 (0)4 74 08 90 00 | |
| Fax: +33 (0) 4 74 08 90 02 | |
| Contact: | Mickaël Nicolas |
| Regulatory Affairs Principal Specialist | |
| 116, avenue du Formans | |
| 01600 Trevoux, France | |
| Phone: +33 (0)4 74 08 90 00 | |
| Email: mickael.nicolas@medtronic.com | |
| Name of device: | |
| Trade/Proprietary name: | Transorb™ Self-Gripping Resorbable Mesh |
| Common name: | Surgical Mesh |
| Classification name: | General And Plastic Surgery Panel number |
| Product code: OWT, FTL, OOD | |
| Regulation number: 21 CFR 878.3300 | |
| Predicate Device: | |
| Trade/Proprietary name: | TIGR® Matrix Surgical Mesh |
| Common name: | Surgical Mesh |
| Classification name: | General And Plastic Surgery Panel number and product code: OWT, FTL, |
| OOD | |
| Regulation number: 21 CFR 878.3300 | |
| 510(k) Number: | K191749 |
| Manufacturer: | Novus Scientific AB, Virdings Alle 2, Uppsala, SE Se-754 50 |
| Reference Device 1: | |
| Trade/Proprietary name: | ProGrip™ Self-Gripping Polyester Mesh |
| Common name: | Surgical Mesh |
| Classification name: | General And Plastic Surgery Panel number and product code: FTL |
| Regulation number: 21 CFR 878.3300 | |
| 510(k) Number: | K220586 |
| Manufacturer: | Sofradim Production (subsidiary of Covidien IIc) |
| 116, avenue du Formans | |
| 01600 Trevoux, France |
4
Reference Device 2:
| Trade/Proprietary name: | Phasix™ Mesh |
|---|---|
| Common name: | Surgical Mesh |
| Classification name: | General And Plastic Surgery Panel number and product code: OOD |
| Regulation number: 21 CFR 878.3300 | |
| 510(k) Number: | K161424 |
| Manufacturer: | Davol Inc. |
| 100 Crossings Boulevard | |
| Warwick, RI 02886 | |
| Device Description: | Transorb™ Self-Gripping Resorbable Mesh is designed for ventral |
| hernia repair when placed in an extraperitoneal space by open surgical | |
| approach. | |
| Transorb™ Self-Gripping Resorbable Mesh is made of a fully resorbable | |
| bi-dimensional Poly-L-lactide, poly-trimethylene carbonate copolymer | |
| (PLLA/TMC) monofilament textile with monofilament PLLA/TMC |
Transorb™ Self-Gripping Resorbable Mesh is available in different shapes and sizes.
Mesh composition:
absorbable grips on one side.
| Product codes | Shape | Dimensions
(length x width) |
|---------------|-------------|--------------------------------|
| TSB1510 | Rectangular | 10cm x 15cm |
| TSB2020 | Square | 20cm x 20cm |
| TSB3030 | Square | 30cm x 30cm |
| TSB4030 | Rectangular | 30cm x 40cm |
Poly-L-lactide, poly-trimethylene carbonate copolymer (PLLA/TMC) monofilament yarn (up to 21g).
The detailed composition refers to the estimated maximum amount of each material and substance to which a patient can be exposed when 1 unit of the largest size of Transorb™ Self-Gripping Resorbable Mesh is implanted (i.e 40 x 30 cm). These amounts will be less for smaller sizes or if the mesh is trimmed by the practitioner prior to implantation.
Transorb™ Self-Gripping Resorbable Mesh is a macro-porous mesh knitted from resorbable monofilament PLLA/TMC yarns. It has been designed to reinforce soft tissues where weakness exists by providing strength and tissue integration throughout the expected healing period. Transorb™ Self-Gripping Resorbable Mesh has absorbable PLLA/TMC grips on one side that facilitate positioning and contribute to fixation. The PLLA/TMC mesh and grips degrade and resorb in vivo by hydrolysis in 36 to 60 months and are metabolized by the body into CO2 and H₂O.
The macro-porous textile provides strength required to withstand biomechanical stresses throughout the healing period, while allowing
5
for tissue ingrowth. As the textile integrates, host tissue ingrowth is intended to provide strength to the repair.
Preclinical studies showed that the mesh maintains mechanical characteristics to reinforce the abdominal wall in vivo for at least 20 weeks and progressively resorbs.
Preclinical studies showed that the grips contribute to the fixation of the mesh to surrounding tissue in vivo for at least 4 weeks.
At 18 to 24 months, mesh degradation is nearly complete. The remaining mesh fibers are essentially resorbed in 36 to 60 months postimplantation. The total resorption period depends on numerous factors including unique patient physiology.
Intended Use:
Transorb™ Self-Gripping Resorbable Mesh is intended to be used for the reinforcement of abdominal wall soft tissues where weakness exists.
Indications for use:
Summary comparing the technological characteristics of the subject, predicate device and reference devices:
Transorb™ Self-Gripping Resorbable Mesh is intended to be used for the reinforcement of abdominal wall soft tissues where weakness exists in open procedures involving ventral hernia repair.
The subject device Transorb™ Self-Gripping Resorbable Mesh is substantially equivalent to the predicate device TIGR® Matrix Surgical Mesh (K191749) in terms of indications.
| | Transorb™ Self-
Gripping
Resorbable Mesh
(K233661) | TIGR® (K191749)
Predicate device | Comparison |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Intended
Use | Reinforcement of
abdominal wall soft
tissue where
weakness exists. | Reinforcement of
soft tissue where
weakness exists. | Similar |
| Indications
for use | Transorb™ self-
gripping resorbable
mesh is intended to
be used for the
reinforcement of
abdominal wall soft
tissues where
weakness exists in
open procedures
involving ventral
hernia repair. | Procedures involving
soft tissue repair,
such as for the repair
of hernias or other
fascial defects that
require the addition
of a reinforcing
material to obtain
the desired surgical
result | Similar |
| Method of
Insertion | Open | Open and
laparoscopic | Similar |
| Location of
Mesh
placement | Extraperitoneal | Extraperitoneal | Same |
| Defect
Closure | Recommended | Recommended | Same |
| Classification | OWT, OOD, FTL per
21 CFR 878.3300 | OWT, OOD, FTL per
21 CFR 878.3300 | Same |
6
| Materials | Fully resorbable
textile (polymeric)
made of copolymer
of polylactide acid
and trimethylene
carbonate yarns
(PLLA/TMC) | Fully resorbable
textile (polymeric)
made of
(i) copolymer of
glycolide, lactide and
trimethylene
carbonate
(PGA/PLA/TMC) and
(ii) copolymer of
lactide and
trimethylene
carbonate
(PLLA/TMC) | Similar |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Shape | Flat Sheet
Square, rectangular,
with round corners | Flat Sheet
Rectangular | Similar |
| Sizes | 10x15cm, 20x20cm,
30x30cm and
30x40cm
The mesh may be
recut as needed | 10x15cm, 15x20cm
and 20x30cm
The mesh may be
recut as needed | Different |
| Texture | Two-dimensional
monofilament
textile with
monofilament
absorbable grips on
one side of the
mesh
Porosity: pore size
of 1.4mm x 1.4mm
at the time of
implantation | Two-dimensional
multifilament textile
Porosity: pore size of
1.0 mm x 1.0 mm at
the time of
implantation | Different |
| Sterilization | Ethylene Oxide | Ethylene Oxide | Same |
Both predicate and subject devices are resorbable flat sheet meshes. Differences in terms of material, sizes, and texture (pore size and presence of grips) have been evaluated and do not raise new questions of safety or effectiveness. Performance testing has demonstrated substantial equivalence for biocompatibility, mechanical properties such as strength, human factors evaluation, sterilization, packaging, and transport.
The device ProGrip™ Self-Gripping Polyester Mesh previously cleared under K220586 is introduced as a reference device for its gripping design feature to support the design of the subject device. Both reference and subject devices have resorbable grips on one side and are equivalent in terms of intended use.
The device Phasix™ Mesh previously cleared under K161424 is introduced as a reference device because it includes large sizes (up to 50*50cm) and it is a fully resorbable mesh. Both reference and subject devices are resorbable meshes with large mesh sizes.
7
Transorb™ Self-Gripping Resorbable Mesh has been evaluated and Materials: found compliant with ISO Standard 10993-1.
Performance data: The performance of Transorb™ Self-Gripping Resorbable Mesh has been evaluated through bench tests, in vitro and in vivo studies. These studies demonstrate that the subject device and predicate device TIGR® Matrix Surgical Mesh (K191749) have substantially equivalent performance characteristics. The following performance data is provided:
a. Biocompatibility Testing
Biocompatibility testing and classification has been selected and performed in accordance with ISO 10993, Biological evaluation of Medical Devices, Part 1: Evaluation and testing within a risk management process. Transorb™ Self-Gripping Resorbable Mesh is classified as an implant with permanent contact.
A complete chemical characterization was performed in accordance with ISO 10993-18. No risk of chronic toxicity, carcinogenicity or reproductive and developmental toxicity has been identified so nor through literature review and material characterization, nor in Toxicological Risk Assessment performed on finished product extractables profile. Available biological safety data on the Transorb™ Self-Gripping Resorbable Mesh are listed hereafter. Testing was performed on sterilized finished devices.
| Studies | Standards | Conclusion |
|---|---|---|
| Cytotoxicity | ISO10993-5 | Pass |
| Sensitization | ISO 10993-10 | Pass |
| Intracutaneous irritation | ISO10993-10 | Pass |
| Acute systemic toxicity | ISO10993-11 | Pass |
| Material mediated pyrogenicity | ISO10993-11 | Pass |
| Hemolysis | ISO 10993-4 | Pass |
| Genotoxicity: bacterial reverse mutation -Ames | ISO10993-3 | Pass |
| Genotoxicity: mouse lymphoma | ISO10993-3 | Pass |
| Subacute systemic toxicity | ISO 10993-11 | Pass |
| Subchronic systemic toxicity | ISO 10993-11 | Pass |
| Local tissue effects (28D - 10W -26W - 52W - 78W) | ISO 10993-6 | Pass |
| In vivo degradation | ISO 10993-9 | Pass |
Applicable ISO 10993-1 Biocompatibility evaluation was conducted and demonstrates that the subject device is biocompatible for its intended body contact and duration.
b. Bench Testing
Bench tests have been performed in accordance with the FDA Guidance "Guidance for the Preparation of a Premarket Notification Application of a Surgical Mesh" issued March 2, 1999 to evaluate the performance characteristics of the subject device Transorb™ Self-Gripping
8
Resorbable Mesh in comparison with the predicate TIGR Matrix Surgical Mesh (K191749). The following finished product physical and mechanical performances were assessed:
| Test method | Applicable standard / Test method | Conclusion |
|---|---|---|
| Pore size | Internal test method. | |
| Mesh pore size is measured on a | ||
| profile projector. Biggest pores | ||
| extreme height and width are | ||
| measured, the sample being free of | ||
| any stresses. | Regarding physical aspect, | |
| the proposed device | ||
| (Transorb™ Self-Gripping | ||
| Resorbable Mesh) is | ||
| substantially equivalent to | ||
| TIGR® Matrix Surgical Mesh | ||
| (K191749). | ||
| Surface | ||
| density | ISO 3801: 1977 | |
| Thickness | ISO 9073-2: 1997 | |
| Bursting | ||
| strength and | ||
| deflection | ASTM 06797-15 | |
| Breaking | ||
| strength and | ||
| elongation at | ||
| break | ISO 13934-1: 2013 | Regarding mechanical |
| aspect in case of 510(k) | ||
| registration, the proposed | ||
| device (Transorb™ Self- | ||
| Gripping Resorbable Mesh) is substantially equivalent | ||
| to TIGR® Matrix Surgical | ||
| Mesh (K191749). | ||
| Tear strength | ISO 4674:1977 - method A2 | |
| Suture pull- | ||
| out strength | Internal test method. | |
| Suture pull-out strength is | ||
| measured on a traction testing | ||
| machine using dedicated specimens | ||
| and test conditions |
c. Animal Testing
Porcine study - Reinforcement performance
In vivo pre-clinical tests on large animal model were conducted in comparison with the predicate TIGR Matrix Surgical Mesh (K191749) to evaluate Transorb™ Self-Gripping Resorbable Mesh reinforcement performance during healing period (up to 20 weeks following implantation):
- o Mechanical performance (breaking strength – ball burst) of the repaired abdominal wall defects sites using a ball burst testing method.
- o Quality of tissue repair and of mesh tissue integration was also assessed by histologic examination.
Rabbit study – Degradation/Integration
In vivo testing has been performed in comparison with predicate TIGR Matrix Surgical Mesh (K191749) to evaluate:
- o Local tissue effects per requirements of ISO 10993-6 (2016) and FDA Guidance Use on International Standard ISO 10993-1, "Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process"
- Tissue integration and tissue ingrowth; O
- Degradation profile O
Porcine study – Gripping performance
9
In vivo testing has been performed in comparison with predicate TIGR Matrix Surgical Mesh (K191749) to evaluate:
- Contribution of the grips to the fixation of the mesh to the o surrounding tissue in early stages after implantation
- Quality of tissue repair and mesh tissue integration by o histologic examination.
These tests demonstrate the safety and performance of the subject device for its intended use and substantial equivalence to the primary predicate device.
d. Human Factors Testing
Usability tests were conducted in accordance with IEC 62366-1 and demonstrate that the subject device Transorb™ Self-Gripping Resorbable Mesh is substantial equivalent for the intended users, uses and use environments.
e. Shelf-life
The shelf-life of the subject Transorb™ Self-Gripping Resorbable Mesh was demonstrated by the results of the real time studies performed on Transorb™ Self-Gripping Resorbable Mesh (representative of final sterile product), that includes testing of the product mechanical performances and the ability of packaging to maintain sterile barrier. Based on these results, a shelf life of 36 months was assigned for the subject Transorb™ Self-Gripping Resorbable Mesh.
f. Clinical data
This premarket submission did not rely on the assessment of clinical performance data to demonstrate substantial equivalence.
Conclusion:
All testing demonstrates that the subject device Transorb™ Self-Gripping Resorbable Mesh is substantially equivalent to the predicate device, TIGR Matrix Surgical Mesh (K191749).